Showing results (451-460 of 556) with videos related to
Sort By:
Pageof 56
Dermatology and Therapy|May 3, 2024
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, H Chih-Ho Hong, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 5, 2023
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry studyKilian Eyerich, Melinda J Gooderham, Juan Francisco Silvestre, et al.Journal of the American Academy of Dermatology|April 8, 2026
Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitisRobert Sidbury, Ali Alikhan, Lionel Bercovitch, et al.JAMA Dermatology|November 3, 2021
Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group ExperienceErin M Warshaw, Michele Buonomo, Joel G DeKoven, et al.JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.Dermatology and Therapy|June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment AdherenceJonathan I Silverberg, Alan D Irvine, Peter Foley, et al.The Journal of Investigative Dermatology|June 29, 2019
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic DermatitisChris Callewaert, Teruaki Nakatsuji, Rob Knight, et al.Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.Dermatitis : Contact, Atopic, Occupational, Drug|May 10, 2021
North American Contact Dermatitis Group Patch Test Results: 2017-2018Joel G DeKoven, Jonathan I Silverberg, Erin M Warshaw, et al.Dermatology and Therapy|June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.Pageof 56